Glepaglutide, a novel glucagon-like peptide-2 agonist, has anti-inflammatory and mucosal regenerative effects in an experimental model of inflammatory bowel disease in rats.

BMC Gastroenterol · 2023 · PMC10029296 · PMID 36944922

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

failed to reach statistical significanceno p-value reported

It was shown that teduglutide had a positive, dose-dependent effect on the CDAI score but that this failed to reach statistical significance.

also in 6,035 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.